Blue Shield of California

Blue Shield | Compliance with SB 729's Fertility Services Requirements

Blue Shield is working in good faith to implement the various requirements of SB 729 for fully-insured small and large employer groups.

Blue Shield | Rx Healthcare Spending Survey Available Now, Due April 19, 2025

Blue Shield of California is collecting D1 Premium Contribution data as part of the Consolidated Appropriations Act, Section 204 (2021)–Survey deadline April 19, 2025.

Blue Shield | Annual Medical Loss Ratio Employer Survey Due 03/31/25

The Blue Shield of California Annual Medical Loss Ratio (MLR) Employer Survey is due March 31, 2025.

Blue Shield | Annual (RxDC) Prescription Healthcare Spending Survey

Blue Shield groups that miss the RxDC survey deadline will not be included in Blue Shield’s filing and may be subject to non-compliance if they do not report the required data directly to the CMS on t...

Blue Shield | Pharmacy Reimagined Official Launch and Continued Learning

Blue Shield proudly launched their new pharmacy supply chain model on January 1, 2025.

Blue Shield | 1095-B Forms Mailed

Blue Shield of California mailed IRS 1095-B forms on January 23 and 24, 2025

Blue Shield | Annual Medical Loss Ratio (MLR) Employer Survey

Blue Shield will send out MLR employer surveys (to groups with

Blue Shield | Committed to Supporting Members Affected by Wildfires

Blue Shield supports members affected by wildfires.

Blue Shield of California Q2 2025 Updates

The second-quarter 2025 rate action is a statewide average of 1.7%. April, May and June renewals will be available January 14th.

Blue Shield | 2025 Pharmacy Change: Amazon Pharmacy Home Delivery

Prescription drug home delivery will shift from CVS Caremark Mail Service Pharmacy to Amazon Pharmacy on January 1, 2025.

Blue Shield | Gag Clause Attestation Due End of Year

Blue Shield of California confirms it is compliant and has successfully submitted the attestation to Centers for Medicare and Medicaid (CMS) services.

Blue Shield's Biosimilar Strategy for Humira

Blue Shield commercial members switching to the biosimilar (adalimumab-aacf) will have $0 cost share.